Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02205294
Other study ID # REB ROMEO # 1017573
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 6, 2014
Est. completion date April 4, 2019

Study information

Verified date June 2023
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Osteopathic treatment will provide: 1. A significant reduction of pain and swelling of the affected DVT leg 2. An increase in the quality of life (QOL) for individuals with DVT of the leg 3. Improved signs and symptoms of the post thrombotic syndrome of the affected DVT leg


Description:

Thousands of individuals are affected by deep vein thrombosis (DVT) every year. Medical treatment is aimed at preventing extension and recurrence of the blood clot (DVT) through the use of anticoagulation medication. Compression stockings may be added for reduction of pain and swelling, but this therapy remains controversial amongst physicians. To date, there is limited manual therapies available for individuals affected with DVT. Regular medical treatment, anticoagulation medication, along with osteopathic treatment may offer these individuals improved control of the symptoms associated with DVT. In the long term osteopathic treatment may provide an increase in the quality of life (QOL) and improve the signs and symptoms associated with the post-thrombotic syndrome (PTS), which can be burdensome for both the individual and the health care system. Offering an effective add on treatment could provide individuals and the medical system with an additional means of treatment for the symptoms of DVT and also for the prevention of development of PTS.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 4, 2019
Est. primary completion date April 4, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - first episode of symptomatic objectively confirmed proximal leg DVT without pulmonary embolism - 1 month of appropriate anticoagulation treatment - therapeutic level of anticoagulation (ie: Warfarin, INR- 2.0-3.0) Exclusion Criteria: - > 1 month + 7 days of anticoagulation - history of previously confirmed proximal or distal leg DVT - medically unstable individuals requiring hospitalization - history of peripheral vascular disease (PVD) - injury of affected leg (trauma within the last 6 months or leg currently casted) - history of previous stroke - uncontrolled hypertension - renal failure requiring hemodialysis or peritoneal dialysis - diagnosis of cancer in the last five years or currently receiving treatment for cancer - open heart or vascular surgery in the last year - any neurological condition (ie: MS, ALS, Parkinsons, etc) - currently pregnant - geographic inaccessibility - unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Osteopathic Treatment
The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.

Locations

Country Name City State
Canada QEll Health Sciences Centre Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Quality of LIfe (QOL) Veines QOL/Sym Questionnaire will be completed by all participants at both study visits to determine if there have been any changes. 1 month and 2 months
Other Assessment for Post Thrombotic Syndrome (PTS) The Villalta scale will be used to assess subjects for signs and symptoms of the post-thrombotic syndrome at both study visits. 1 month and 2 months
Primary Swelling Swelling will be measured using a tension-controlled tape measure at the initial study visit, one month after diagnosis of the subject's DVT and then again at 2 months after diagnosis. 1 month pre and post testing and 2 months
Secondary Leg Pain Leg Pain will be measured using the visual analogue scale (VAS), at the initial study visit(1 month after diagnosis of the DVT) pre and post assessment or assessment plus treatment. Pain will be evaluated again at the 2 month visit post answering questionnaires and lying supine for 10 minutes. 1 month pre and post testing and 2 months
See also
  Status Clinical Trial Phase
Completed NCT02523937 - Evaluation of Soluble Fibrin in Thrombosis Exclusion
Terminated NCT03805672 - Below Knee DVT Study Phase 4
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Completed NCT02798471 - Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Phase 3
Completed NCT02210819 - Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Completed NCT01630148 - Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries N/A
Completed NCT02073682 - Cancer Venous Thromboembolism (VTE) Phase 3
Recruiting NCT06195787 - Improving Emergency Department Testing for Deep Vein Thrombosis
Recruiting NCT02342444 - Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD) Phase 4
Completed NCT02744092 - Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer N/A
Recruiting NCT02156401 - VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE